This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 342 total patients will be randomized to study treatment (selinexor or placebo).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Timeframe: From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)
Phase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1
Timeframe: From the date of randomization in the Phase 3 open label period until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)
Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1
Timeframe: From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)
Phase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1
Timeframe: From date of randomization in the Phase 2 open label period until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)